1. Neuroendocrine disorders of the gastroenteropancreatic system. Clinical applications of the somatostatin analogue SMS 201-995 (Octreotide, Sandostatin). April 2-4, 1986, San Diego, California;Am J Med,1986
2. Approved drug products with therapeutic equivalence evaluations, 39th edition US Department of Health and Human Services Food and Drug Administration. 2019:vol. 3;326. Available at: https://www.fda.gov/media/71474/download.
3. 90Y-edotreotide for metastatic carcinoid refractory to octreotide;Bushnell;J Clin Oncol,2010
4. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017
5. Gut endocrinology: clinical and therapeutic impact;O'Dorisio;Am J Med,1986